Axiom Investors LLC DE Sells 4,922 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Axiom Investors LLC DE decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 96,850 shares of the medical equipment provider's stock after selling 4,922 shares during the quarter. Axiom Investors LLC DE owned approximately 0.14% of Lantheus worth $8,664,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of LNTH. Wellington Management Group LLP bought a new stake in shares of Lantheus during the 4th quarter valued at $20,022,000. Summit Securities Group LLC bought a new stake in Lantheus in the fourth quarter valued at approximately $37,000. Allianz SE bought a new position in shares of Lantheus during the fourth quarter worth $346,000. Pictet Asset Management Holding SA increased its position in shares of Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after buying an additional 1,113 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new position in Lantheus during the fourth quarter worth about $1,365,000. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Finally, Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Stock Down 5.2 %

Shares of Lantheus stock traded down $5.09 during trading on Friday, reaching $92.12. The company's stock had a trading volume of 371,498 shares, compared to its average volume of 939,869. The business's 50-day moving average price is $93.45 and its 200-day moving average price is $96.30. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The firm has a market cap of $6.31 billion, a PE ratio of 15.40 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 over the last three months. Insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.